Lilly Sets Up Next-Gen Obesity Battle With Full Phase 3 Retatrutide Data

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the top dose of the triple-G drug candidate lost at least 25% of their body weight. Lilly reported topline data from the trial, Tri ...Read more